Lower Gastrointestinal NET Clinical case One patient and how many doctors ? Dimitrios Dimitroulopoulos MD, PhD Consultant Gastroenterology Dpt. “Agios.

Slides:



Advertisements
Similar presentations
The Thyroid Incidentaloma
Advertisements

Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.
IMAGE CHALLENGE. A 51-year-old woman with a history of hypertension and chronic constipation presented with abdominal pain of 2 weeks' duration. The.
Carcinoma scarsamente differenziato Terapia radiorecettoriale
January 2007 Clinical Cases. BACKGROUND A 57-year-old man presents to a local emergency department with severe abdominal pain after being evacuated from.
First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Colon Cancer Treatment The Perspective of a Medical Oncologist
Ayman Abdo MD, AmBIM, FRCPC
Project Intern BY: CEDRIC, MIKE, AND NICK. Ben Johannson  Ben Johannsson showed up at the doctors office with multiple symptoms including: fluid retention,
Case Presentation: Neuroendocrine Tumor in the Midgut
Colorectal cancer Khayal AlKhayal MD,FRCSC
Atypical and aggressive meningiomas: Is there a role for radiologists in guiding treatment? #EP-53 Anthony Galinato MD, Feras Mossa-Basha MD, Ishani Dalal.
Joint Hospital Surgical Grand Round 21 st July, 2012 RH.
GASTROINTESTINAL RADIOLOGY : GI 4. INTRODUCTION - Primary gastrointestinal malignant melanoma is an unusual clinical entity. Rarer still is primary gastric.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.
Methotrexate- induced rheumatoid nodules in the liver and spleen masquerading metastatic malignancy: a case report Maria Kosmidou 1, Paraskeyi Kotsi 1,
Living Beyond Breast Cancer Liver and Lung Metastases Workshop April 29, 2012 Paul B. Gilman, MDLankenau Medical Center.
NYU Medical Grand Rounds Clinical Vignette Elizabeth Selden, MD PGY-2 November 8, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Ovarian tumor Wei Jiang, M.D., Ph.D. Attending of Ob & Gyn Ob & Gyn Hospital, Fudan University 419 Fangxie Road, Shanghai -----From.
Guzman, Alexander Joseph Hipolito, April Lorraine
Unit of Gastrenterology Unit of Endocrinology THEAGENIO Hospital, Thessaloniki Metastatic neuroendocrine tumor of the jejunum-ileum.
SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,
Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.
ΝΕΤ MasterClass 2015 ΙΩΑΝΝΗΣ ΠΙΛΠΙΛΙΔΗΣ, MD, FEBGH
Case 1 45 y male Large ulcer on right leg months ON examination An ulcer measuring 4x6 cm on medial Aspect of right leg just above the ankle joint.
Interesting Case Presentation Neuroendocrine Lung Tumors M. Demiri B Oncology Clinic Director Saint Savvas Anticancer Hospital.
ER and PR Test Estrogen and Progesterone receptor status tests will show whether or not one or both of these hormones fuel the tumor Cancer that is hormone-sensitive.
1 CAP Audio Conference on the CMS 2009 Physician Quality Reporting Initiative Jonathan Myles, MD, FCAP College of American Pathologists December 17, 2008.
Endocrinology Unit Pathophysiology Department Laikon General Hospital Case Presentation: Dr. Chatzellis Eleftherios MD Intern in Endocrinology.
Blatchford score is a useful tool for predicting the need for intervention in cancer patients with upper gastrointestinal bleeding. Ahn S, Lim KS, Lee.
Clinical Correlations The NYU Internal Medicine Blog A Daily Dose of Medicine
Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.
NYU Medical Grand Rounds Clinical Vignette Lisa Cioce MD, PGY-2 March 10, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Anal Cancer - Case 1  62 years old woman with 6 months history of anal pain  Clinically T 3 squamous cell carcinoma growing anteriorly  Which staging.
NYU Medicine Grand Rounds Clinical Vignette David Altszuler, MD PGY-2 December 11, 2013 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
PROTOCOL GO29294 A study evaluating a potential new treatment for locally advanced or metastatic urothelial bladder cancer VERSION 1 | 19 SEPTEMBER 2014.
Accuracy of EUS in diagnosis of rectal cancer KKUH experience
Hospital Departments, Staff and Equipments
Clinical Correlations The NYU Internal Medicine Blog A Daily Dose of Medicine
Neuroendocrine Tumours
Pancreatic cancer.
Healthy Living Project By: Soila Magdalena Douce
HEAPHY 1 & 2 CASE RACE 1 – DIAG Yvonne CLARKE Sat 31 st Aug 2013 Session 3 / CR1-4 13:16 – 13:20 WELLINGTON ABSTRACT Following a woman’s pathway from her.
NEOPLASIA CASES. CASE 1 A 20 year old female presented with a round mobile breast lump. She has no family history of breast cancer Question : What test.
Introduction to Tumor Board
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Laura Finucane Masqueraders course March 2012 Laura Finucane 2011 © Bony Metastases.
Case. Kreem is 53 year old man who is quite healthy with no previous illness. He has noticed changes in his bowel habits for the last few months, with.
Diagnosis and Management Pearls
ENDOSCOPIC MUCOSAL RESECTION OF NON INVASIVE DUODENAL CARCINOID
CASE 1: Management of metastatic disease in a resource-limited setting
Ari Brooks, MD Cancer Surgeon, Big Data End User
‘Piloting change’ report on the Multi Disciplinary Diagnostic centre
1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)
Basile Pache, Antonia Digklia*, Nicolas Demartines, Maurice Matter.
Fig. 4. Follow-up abdominal computed tomography scans after six cycles of S-1/cisplatin combination chemotherapy (A, B) and 68 months after surgery (C,
Pancreatic carcinoma in young patient
Neo-adjuvant treatment for metastatic colon cancer in geriatric patients followed by simultaneous hepatic resection: A case report Sotiropoulos GC, Machairas.
2epart EXTRAPULMONARY SMALL CELL CANCER OF THE ESOPHAGUS INTRODUCTION
Michael Lin, Jenn Hian Koo, David Abi–Hanna 
Metastatic Breast cancer
AFP > 9000 without demonstrable HCC
Evaluate the results of concomitance chemoradiotherapy postoperative treatment for rectal cancer in stage II-III At K Hospital from 2012 to 2016 Speaker:
General strategies of Cancer Treatment and evaluation of Response
Colon Doctor San Antonio
January 2007 Clinical Cases.
Presentation transcript:

Lower Gastrointestinal NET Clinical case One patient and how many doctors ? Dimitrios Dimitroulopoulos MD, PhD Consultant Gastroenterology Dpt. “Agios Savvas” Cancer Hospital of Athens NET Masterclass

The first contact 2007 The family doctor Female,50 years old, without previous history of serious illness and without family history of cancer, underwent some routine blood tests and radiology examinations ordered by their GP, due to thoracic pain. CT scans revealed focal liver lesions and a wall thickness in the lower sigmoid colon area.

Diagnosis 2008 The initial hospital contact Hospitalization in Athens hospital for further investigation. Endoscopic examination of the lower digestive tract revealed at 35 cm from the anal canal a large lesion. Pathology report : Neuroendocrine tumor of colon. NO treatment decision.

Searching for a “solution” 2008 Visiting several surgeons The patient was consulted by three surgeons in different private hospitals. Two of them proposed surgery and chemotherapy and the third surgery and chemoembolization for the focal liver lesions, and if this was not adequate, RF. The patient in this period was without symptoms and in good performance status. CEA 14.9 ng/ml (UNL 7,00).

Searching for a “solution” 2009 Visiting a surgeon in a cancer hospital The patient was consulted by a surgeon in a cancer hospital of Athens. Patient’s decision : “This is the perfect doctor for me”. Doctor’s decision : Due to good performance status and the “fear of massive intraoperative hemorrhage during the operation” the doctor decided re-staging Hospitalization in surgery department. Imaging and laboratory tests focused to the disease (hormones, somatostatine receptors scintigraphy etc) Octreoscan revealed intraperitoneal metastatic lymph nodes.

Initial therapeutic approach 2009 Administration of radiolabeled In 111 Four doses of Octreoscan In mCi (09/2009 – 02/2010) were administered. Three months later, control examinations reported “stability and maybe a small remission of the disease” (according to the report of the responsible nuclear medicine doctor).

Nuclear medicine treatment continue… Y-DOTATOC MRI scans reported progressive metastatic liver disease. The attendant (surgeon) decided a new nuclear medicine treatment with 90 Y- DOTATOC. The patient underwent three cycles with 90 Y-DOTATOC administration in the state cancer hospital of Salonika.

Nuclear medicine treatment continue… Dead of attendant doctor. The follow up and the management is made now by the gastroenterology Dpt. of the state cancer hospital of Salonika. Re-staging : Stable disease. No other therapeutic approach.

Nuclear medicine treatment continue… Y-DOTATOC CT and MRI scans revealed progression of the disease in the liver. The patient decided to entrust herself to another doctor Decision for re-treatment with 90 Y-DOTATOC (3 cycles). Six months after, stable disease.

Administration of somatostatin analogue 2013 JAN 2013 : Administration of a somatostatin analogue (every 28 days). APR 2013 : According to a new Octreoscan report “the patient present’s significant scintigraphic improvement in comparison with an examination of JUL 2013”. Laboratory, imaging and endoscopic examination without any changes. CEA 8,6 (UNL 4,7 ng/ml). Good performance status.

Progression 2014 MAR 2014 : Loss of weight (12 Kg in 4 months). Laboratory examinations : Diabetes mellitus, CEA 52,1 ng/ml (UNL 4,7), NSE 89 ng/ml (UNL 16,3), ALP 400 U/l, γ-GT 187, LDH 310. Imaging examinations : Disease progression. Octreoscan and endoscopy pending

... and now what ? (…and how many doctors ?)